NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Syndax Pharmaceuticals, Inc. (SNDX) Stock Analysis

Syndax Pharmaceuticals, Inc. (SNDX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

SNDX

$20.56

−$0.12 (−0.58%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SNDX with… →

SNDX Key Statistics

As of Sep 4, 2026
Trading
Open
$20.46
Previous Close
$20.68
Day's Range
20.46–21.00
52-Week Range
12.99–25.59
Volume
1.36M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.37
Valuation
Market Cap
$1.84B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
7.28
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.50
Financials (FY)
Revenue (FY)
$172.35M+627.84%
Net Income (FY)
−$285.42M
Profit marginThe share of revenue left as profit after all costs and taxes.
−87.52%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
89.30M
1-Year Return
+26.99%
Dividend and dates
Earnings Date
November 2, 2026estimated
Avg Volume
1.70M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SNDX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−2.14%
2025+58.93%
2024−38.82%
2023−15.09%
2022+16.26%
2021−1.57%
2020+153.30%
2019+97.30%
2018−49.20%
2017+22.18%
2016 (partial year)−46.01%

As of September 4, 2026.

SNDX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$172.35M−$285.42M−165.6%
2024$23.68M−$318.76M−1346.1%
2023$0.00−$209.36M—
2022$0.00−$149.34M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$172.35M$165.38M−$273.08M−$285.42M−165.6%
2024$23.68M$22.85M−$339.67M−$318.76M−1346.1%
2023$0.00$0.00−$229.95M−$209.36M—
2022$0.00$0.00−$151.76M−$149.34M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SNDX Valuation vs Biotechnology Median

Median of 656 stocks
MetricSNDXBiotechnology medianvs median
P/S ratio7.2815.2652% below
Profit margin−87.52%0.00%87.5 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Syndax Pharmaceuticals, Inc. (SNDX) at $1.84B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 298.

The most recent close on file for SNDX is $20.56, dated September 4, 2026. That is −$0.12 (−0.58%) against the previous close. Over the past 52 weeks the price has ranged from $12.99 to $25.59. The latest close sits 58.28% above that 52-week low.

Financial Health

In fiscal 2025, Syndax Pharmaceuticals, Inc. reported revenue of $172.35M. Against the prior fiscal year total of $23.68M, that is a change of +627.84%. The same year closed with a net loss of $285.42M. The reported profit margin is −87.52%. That is 87.5 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −2.5.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $172.35M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 7.28. On price-to-sales that is 52.32% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.37. Daily returns over the trailing 10 years annualize to a volatility of 70.66%. The trailing one-year price return is +26.99%. Measured over 10 years, that is +3.91% a year compounded.

Growth & Income

No dividend is on file for SNDX.

The strongest complete calendar year on file is 2020 at +153.30%; the weakest is 2018 at −49.20%. Of the 9 complete calendar years on file, 5 finished higher. So far in 2026 the price is −2.14%.

Peer Comparison

Syndax Pharmaceuticals, Inc. (SNDX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Syndax Pharmaceuticals, Inc. SNDX $1.84B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Syndax Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

Visit website →